Cartesian Therapeutics (RNAC) Current Deferred Revenue (2015 - 2024)
Cartesian Therapeutics (RNAC) posted quarterly Current Deferred Revenue of $412000.0 for Q1 2024, down 90.26% year-over-year from $4.2 million in Q2 2023, and down 82.17% quarter-over-quarter from $2.3 million in Q4 2023.
Cartesian Therapeutics (RNAC) Current Deferred Revenue (2015 - 2024) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Current Deferred Revenue for 10 consecutive years, with $412000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Current Deferred Revenue fell 90.26% year-over-year to $412000.0; the TTM figure through Mar 2024 stood at $412000.0 (down 90.26% YoY), while the FY2023 annual figure was $2.3 million, up 289.71% from the prior year.
- Current Deferred Revenue declined to $412000.0 in Q1 2024 per RNAC's latest filing, from $2.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $115.8 million in Q3 2020 and bottomed at $412000.0 in Q1 2024.
- Historically, Current Deferred Revenue has averaged $34.4 million across 5 years, with a median of $9.2 million in 2021.
- Annual changes were most pronounced in 2020 — Current Deferred Revenue soared 11223.46% — and 2022, when it sank 93.55%.
- Cartesian Therapeutics' Current Deferred Revenue stood at $110.8 million in 2020, then sank by 91.7% to $9.2 million in 2021, then tumbled by 93.55% to $593000.0 in 2022, then jumped by 289.71% to $2.3 million in 2023, then plunged by 82.17% to $412000.0 in 2024.
- Business Quant data shows RNAC's Current Deferred Revenue at $412000.0 in Q1 2024, $2.3 million in Q4 2023, and $4.1 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 412,000.00 |
| Dec 31, 2023 | 2.31 Mn |
| Sep 30, 2023 | 4.14 Mn |
| Jun 30, 2023 | 4.23 Mn |
| Mar 31, 2023 | 4.23 Mn |
| Dec 31, 2022 | 593,000.00 |
| Sep 30, 2022 | 9.26 Mn |
| Jun 30, 2022 | 23.09 Mn |
| Mar 31, 2022 | 38.41 Mn |
| Dec 31, 2021 | 9.20 Mn |
| Sep 30, 2021 | 82.37 Mn |
| Jun 30, 2021 | 99.75 Mn |
| Mar 31, 2021 | 75.76 Mn |
| Dec 31, 2020 | 110.80 Mn |
| Sep 30, 2020 | 115.84 Mn |
| Jun 30, 2020 | 1.93 Mn |
| Mar 31, 2020 | 1.67 Mn |
| Dec 31, 2019 | 1.67 Mn |
| Sep 30, 2019 | 1.02 Mn |
| Jun 30, 2019 | 1.02 Mn |